| Literature DB >> 35146296 |
Michael Porst1, Annelene Wengler1, Janko Leddin1, Hannelore Neuhauser1, Zaza Katsarava2,3,4,5, Elena von der Lippe1, Aline Anton1, Thomas Ziese1, Alexander Rommel1.
Abstract
Headache disorders are widespread among women and men in Germany and are primarily associated with restrictions on quality of life. The two most common types of headache disorders are migraine and tension-type headache. In order to gain valid estimates of the prevalence of these conditions, a cross-sectional telephone-based survey was conducted among adults in Germany (N=5,009) between October 2019 and March 2020. The frequency, duration, the characteristics and comorbidities associated with headache were measured using the diagnostic criteria defined in the International Classification of Headache Disorders. 57.5% of women and 44.4% of men in Germany stated that they had had a headache in the last twelve months. 14.8% of women and 6.0% of men meet all of the diagnostic criteria for migraine. Tension-type headache affects 10.3% of women and 6.5% of men. Migraine and tension-type headache are predominantly found among people of working age and steadily decrease with age. Migraine is often accompanied by comorbidities such as depressive symptoms and anxiety disorders. People affected by headache disorders tend to receive very little professional medical care, with only a minority seeking treatment within a year. These results provide a comprehensive picture of the population-related impact of headache disorders and are used in the BURDEN 2020 study to quantify key indicators for burden of disease assessment. © Robert Koch Institute. All rights reserved unless explicitly granted.Entities:
Keywords: BURDEN OF DISEASE; COMORBIDITIES; MEDICATION; MIGRAINE; TENSION-TYPE HEADACHE
Year: 2020 PMID: 35146296 PMCID: PMC8734075 DOI: 10.25646/6990.2
Source DB: PubMed Journal: J Health Monit ISSN: 2511-2708
Indicators to measure migraine and tension-type headache
Source: Own table
|
|
| |
| A. Frequency | At least five episodes over a person’s lifetime | At least ten episodes of headache occurring over a person’s lifetime |
| B. Duration of the attacks | 4–72 hours (when untreated or unsuccessfully treated) | Lasting from 30 minutes to seven days (when untreated or unsuccessfully treated) |
| C. Characteristics | At least two of the following four characteristics:
unilateral location Pulsating quality Moderate or severe pain intensity Aggravation by or causing avoidance of routine physical activity (e.g. walking or climbing stairs) | At least two of the following four characteristics:
Bilateral location Pressing ot tightening (non-pulsating) quality Mild or moderate intensity Not aggravated by routine physical activity such as walking or climbing stairs |
| D. Comorbidities | During headache at least one of the following:
Nausea and/or vomiting Photophobia or phonophobia | Both criteria are met:
No nausea or vomiting No more than one of photophobia or phonophobia |
|
|
| |
|
Criteria for Migraine (without Aura) are fulfilled In addition, the person fulfills at least one of the following criteria: Experiencing flimmer or flash in front of eyes, for at least 5 minutes Weakness, paralysis or numbness of limbs, or impaired speech |
Figure 1Schematic representation of headache based on the Global Burden of Disease study
Source: Own diagram
The sociodemographic characteristics of the study population compared with official statistics
Source: Study on headache, back and neck pain in Germany (2019/2020), Destatis population update*
| Study on pain disorders | Official statistics | |
|---|---|---|
|
| ||
| Women | 52,6% | 51,1% |
| Men | 47,4% | 48,9% |
|
| ||
| 18–29 years | 9,2% | 16,6% |
| 30–39 years | 11,4% | 15,3% |
| 40–49 years | 13,8% | 15,0% |
| 50–59 years | 21,6% | 19,4% |
| 60–69 years | 21,7% | 14,8% |
| ≥70 years | 22,4% | 18,8% |
|
| ||
| Low | 5,0% | 17,5% |
| Medium (no Abitur) | 29,7% | 41,9% |
| Medium (has Abitur) | 13,0% | 15,4% |
| High | 52,4% | 25,2% |
* Official statistics based on the population update (as of 31 December 2018) and the results of the 2017 microcensus.
Figure 2Prevalence of migraine and tension-type headache in adults by sex and age (n=2,634 women, n=2,375 men)
Source: Study on headache, back and neck pain in Germany (2019/2020)
Figure 3Distribution of headache in the past twelve months by headache type (N=5,009)
Source: Study on headache, back and neck pain in Germany (2019/2020)
Figure 4Intensity of headache, including (definite) migraine and (definite) tension-type headache
Source: Study on headache, back and neck pain in Germany (2019/2020)
Frequency per month and duration for headache in general, (definite) migraine and (definite) tension-type headache
Source: Study on headache, back and neck pain in Germany (2019/2020)
| Sex | Headache | Migraine | Tension-type headache | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AM | MD | STD | AM | MD | STD | AM | MD | STD | ||
| Days with a headache (in days per month) | Women |
| 1.0 | 5.3 | 4.0 | 1.5 | 6.2 | 2.6 | 1.0 | 4.5 |
| (n=1,321) | (n=332) | (n=231) | ||||||||
| Men |
| 1.0 | 4.6 | 4.4 | 1.0 | 6.6 | 2.2 | 1.0 | 4.0 | |
| (n=958) | (n=111) | (n=143) | ||||||||
| Duration of the headache (in days) | Women | 1.0 | 0.1 | 2.1 |
| 1.0 | 1.1 | 0.6 | 0.1 | 1.1 |
| (n=1,289) | (n=340) | (n=235) | ||||||||
| Men | 0.8 | 0.1 | 2.4 |
| 1.0 | 0.7 | 0.6 | 0.1 | 0.8 | |
| (n=936) | (n=113) | (n=148) | ||||||||
Bold = A significant difference in the mean between women and men (p-value <0.05)
AM = mean, MD = median, STD = standard deviation
Figure 5Intensity of headache over the past twelve months by frequency of attack per month (n=1,320 women, n=957 men)
Source: Study on headache, back and neck pain in Germany (2019/2020)
The most common comorbidities
Source: Study on headache, back and neck pain in Germany (2019/2020)
| Back pain | Neck pain | Depressive symptoms | Anxiety disorder | |
|---|---|---|---|---|
| Migraine (definite) (n=449) |
|
|
|
|
| Tension-type headache (definite) (n=383) |
|
| 12,6 % | 10,2 % |
| No headache[ | 12,6 % | 6,7 % | 15,3 % | 8,7 % |
1 People answered ‘No’ to the question ‘Have you had a headache in the past twelve months?’
Bold = Significant difference (p-value <0.05) compared with participants without headache; comparison based on the Pearson χ2 test
Use of medication to treat headache (percentage of all responses, multiple answers possible)[1]
Source: Study on headache, back and neck pain in Germany (2019/2020)
| Medication | Headache | Medication | Migraine | Medication | Tension-type headache |
|---|---|---|---|---|---|
| Ibuprofen | 49.7% | Ibuprofen | 46.2% | Ibuprofen | 47.8% |
| Paracetamol | 18.7% | Paracetamol | 17.1% | Paracetamol | 22.5% |
| Acetylsalicylic acid | 15.0% | Acetylsalicylic acid | 10.2% | Acetylsalicylic acid | 14.9% |
| Metamizole sodium | 6.0% | Metamizole sodium | 9.3% | Metamizole sodium | 4.0% |
| Triptan | 2.8% | Triptan | 7.3% | Diclofenac | 2.6% |
| Diclofenac | 2.3% | Diclofenac | 2.4% | Triptan | 2.4% |
| Naproxen | 0.9% | Naproxen | 1.2% | Celecoxib | 1.0% |
| Tilidine | 0.5% | Tramadol | 0.7% | Naproxen | 1.0% |
| Mentions | 2,320 | Mentions | 578 | Mentions | 423 |
| Respondents | 2,349 | Respondents | 453 | Respondents | 383 |
1 This table only provides the figures for the eight most commonly mentioned drugs. The figures shown are unweighted.
Multinomial regression of the social determinants of (definite) migraine and (definite) tension-type headache (n=2,526 women, n=2,280 men)[1]
Source: Study on headache, back and neck pain in Germany (2019/2020)
| Migraine (definite) | Tension-type headache (definite) | |||||
|---|---|---|---|---|---|---|
| OR[ | p-value | (95% CI) | OR[ | p-value | (95% CI) | |
|
| ||||||
| Women |
| <0.001 | (3.22–6.80) |
| <0.001 | (1.85–3.80) |
|
| ||||||
| 30–<40 years | 0.79 | n.s. | (0.43–1.47) | 1.65 | n.s. | (0.84–3.25) |
| 40–<50 years |
| <0.01 | (0.26–0.80) | 0.69 | n.s. | (0.34–1.38) |
| 50–<60 years |
| <0.001 | (0.13–0.39) |
| <0.01 | (0.20–0.66) |
| 60–<70 years |
| <0.001 | (0.03–0.13) |
| <0.001 | (0.11–0.39) |
| ≥70 years |
| <0.001 | (0.01–0.04) |
| <0.001 | (0.03–0.16) |
|
| ||||||
| Low | 0.49 | n.s. | (0.25–0.99) | 0.57 | n.s. | (0.27–1.20) |
| High | 0.95 | n.s. | (0.70–1.29) | 0.75 | n.s. | (0.54–1.02) |
|
| 2.11 | n.s. | (0.76–5.83) | 0.81 | n.s. | (0.24–2.74) |
|
| 1.05 | n.s. | (0.73–1.52) | 0.94 | n.s. | (0.63–1.39) |
|
| ||||||
| Low | 1.24 | n.s. | (0.76–2.02) | 1.03 | n.s. | (0.55–1.92) |
| High |
| <0.05 | (0.44–0.91) | 0.77 | n.s. | (0.54–1.12) |
OR = odds ratio, 95% CI = 95% confidence interval, bold = significant (p <0.05), n.s. = not significant
1 All participants who answered ‘No’ to the initial question ‘Have you had a headache in the past twelve months?’ were used as the reference group in the multinomial logistic regression.
2 In multinominal logistic regression relative risk ratios (RRR) are computed to express the strength of ststistical associations. Usually, these are interpreted as odds ratios.